WEBIMFINZI is a monoclonal antibody for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) expressing PD-L1. The recommended dose is 10 mg/kg every 2 weeks by intravenous infusion, with dose modifications for immune-mediated adverse reactions.
Imfinzi - European Medicines Agency (EMA)
WEBImfinzi is a medicine used to treat various types of cancer, including lung, biliary, liver and endometrial cancer. It contains the active substance durvalumab, a monoclonal antibody that blocks PD-L1, a protein that helps cancer cells evade the immune system.
WEBIMFINZI contains the active substance durvalumab which is a monoclonal antibody, a type of protein designed to recognise a specific target substance in the body. IMFINZI works by helping your immune system fight your cancer.
WEBIMFINZI is a concentrate for solution for infusion containing durvalumab, a monoclonal antibody for the treatment of various cancers. The document provides information on the indications, posology, method of administration, and storage of IMFINZI.
DailyMed - IMFINZI- durvalumab injection, solution
WEBAug 15, 2024 · IMFINZI is a PD-L1 blocking antibody for certain cancers. It is supplied as a clear to opalescent, colorless to slightly yellow solution in a single-dose vial. See prescribing information, warnings, adverse reactions, and more.
What is IMFINZI® (durvalumab) – Treatment for Bile Duct Cancer ...
WEBIMFINZI is a prescription medicine that works with your immune system to treat locally advanced or metastatic bile duct cancer or gallbladder cancer. It is used in combination with chemotherapy medicines gemcitabine and cisplatin and can cause serious side effects.
WEBThe active substance of Imfinzi is durvalumab, an antineoplastic monoclonal antibody (ATC code: L01XC28) that potentiates T-cell response, including anti-tumour response, through blockade of PD -L1 binding to PD-1.
WEBImfinzi is a monoclonal antibody used to treat bladder, lung and biliary tract cancers. It can cause serious side effects such as allergic reactions, immune system problems and organ damage.
How Does IMFINZI® (durvalumab) Work
WEBIMFINZI is an immunotherapy that works with your immune system to fight non-small cell lung cancer (NSCLC) that has not spread outside your chest. Learn how IMFINZI works, what side effects it may cause, and how to get info and support.
Imfinzi 50 mg/mL concentrate for solution for infusion
WEBIMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements.